化疗在晚期和复发性子宫内膜癌的成本效益
1Department of Obstetrics and Gynecology, Fujinomiya City General Hospital, 3-1 Nishiki-cho, Fujinomiya, Shizuoka, Japan.
Gynecologic oncology reports
|June 9, 2025
概括
免疫疗法与化疗相结合,为晚期子宫内膜癌提供了生存益处,特别是在不匹配修复缺陷 (dMMR) 瘤中. 成本效益因瘤类型和治疗方案而异,可能需要降低价格以获得更广泛的经济可行性.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
背景情况:
- 子宫内膜癌治疗随着免疫治疗的整合而发展.
- 评估新疗法的经济价值对于临床采用至关重要.
研究的目的:
- 评估化学疗法和免疫疗法治疗晚期和复发性子宫内膜癌的成本效益.
- 为了确定各种治疗策略的增量成本效益比率 (ICER).
主要方法:
- 2021年至2025年间发表的同行评审研究的文献综述.
- 对比免疫检查点抑制剂 (ICI) 与化疗或向药物与标准化疗的研究分析.
- 提取关键结果,包括每QALY获得的成本和支付意愿 (WTP) 门.
主要成果:
- 一线ICI加化疗在15万美元/QALY值时,证明了对不匹配修复缺陷 (dMMR) 的子宫内膜癌的成本效益.
- 对于不匹配修复熟练 (pMMR) 患者和二线治疗,ICERs经常超过WTP值,表明成本效益较低.
- 特殊组合如杜尔瓦卢马布+奥拉帕里布和潘布罗利祖马布+伦瓦提尼布在没有降价的情况下,在大多数场景中显示成本效益较差.
结论:
- 免疫检查点抑制剂 (ICI) 在晚期子宫内膜癌中提供临床优势,特别是在dMMR瘤中.
- 第一线ICI加上化疗在美国支付意愿水平内对dMMR疾病具有成本效益.
- 在pMMR或后代设置中的成本效益可能需要降低药物价格或以生物标志物为指导的患者选择.
关键词:
晚期的癌症 晚期的癌症化疗 化疗是一种化学疗法.经济效益性 经济效益性这是子宫内膜癌的癌症.卫生经济学 卫生经济学免疫治疗是一种免疫疗法.增量性成本效益比率是一种增量性成本效益比率.癌症的复发是癌症的复发.更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
11.3K
相关概念视频
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
179
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
179
01:21Cancer Survival Analysis
329
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
329
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
152
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
152